Xenon Pharmaceuticals (XENE) Given Daily Media Impact Rating of 0.26
Media stories about Xenon Pharmaceuticals (NASDAQ:XENE) have trended positive this week, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Xenon Pharmaceuticals earned a news sentiment score of 0.26 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 47.785045636085 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Xenon Pharmaceuticals, Inc. (XENE) CEO Dr. Simon Pimstone on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Jefferies Financial Group Reiterates Buy Rating for Xenon Pharmaceuticals (XENE) (americanbankingnews.com)
- Top Loser: Syndax Pharmaceuticals, Inc. (SNDX) shows decline of 11.13% on trading volume of 475995 shares (topdesertsafari.com)
- Xenon (XENE) Receives a Buy from Jefferies (analystratings.com)
- Top Losers: Technical highlights of Superior Industries International, Inc. (SUP) and Xenon Pharmaceuticals Inc … (topdesertsafari.com)
Shares of NASDAQ XENE traded down $0.35 during mid-day trading on Friday, hitting $11.75. The stock had a trading volume of 153,241 shares, compared to its average volume of 139,125. The company has a debt-to-equity ratio of 0.41, a current ratio of 20.83 and a quick ratio of 9.70. Xenon Pharmaceuticals has a twelve month low of $2.10 and a twelve month high of $12.15. The company has a market cap of $171.48 million, a price-to-earnings ratio of -6.83 and a beta of 0.68.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research downgraded Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Jefferies Financial Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Xenon Pharmaceuticals in a research report on Friday. Stifel Nicolaus upped their price target on Xenon Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, ValuEngine raised Xenon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.
Recommended Story: What is a closed-end mutual fund (CEF)?
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.